Characteristics of CD5-positive diffuse large B-cell lymphoma among Koreans: High incidence of BCL2 and MYC double-expressors

• DOI: 10.1371/journal.pone.0224247
• Publication Date: 2019-10-23T18:11:28Z
• Authors: Hee Young Na; Ji-Young Choe; Sun Ah Shin; Hyun-Jung Kim; Jae Ho Han; Hee Kyung Kim; So Hee Oh; Ji Eun Kim
• Keywords: CD5; Immunophenotyping

Aberrant expression of CD5 has been reported in 5-10% diffuse large B-cell lymphomas (DLBCLs). CD5+ DLBCL had recognized as an aggressive immunophenotypic subgroup the 2008 WHO classification haematolymphoid neoplasm; however, it was eliminated from list subgroups DLBCLs revised 2016 classification. Nevertheless, there is much controversy regarding clinical significance expression, and many researchers still assert that this exhibits extremely unfavorable prognosis with frequent treatment failure. We retrospectively investigated 405 recruited three university hospitals Korea 1997 to 2013. The profile, immunophenotype, chromosomal structural alterations BCL2 MYC genes were compared according expression. A total 29 cases de novo identified out our series (7.4%). Clinicopathologic correlation performed all 166 CD5- which eligible for full review further pathologic examination. Compared counterparts, showed female preponderance, bone marrow involvement, higher lactate dehydrogenase level, advanced Ann Arbor stages poorer (all p<0.05). Pathologically, positively correlated BCL2, Ki-67 Coexpression MYC, referred a double-expressor, relatively more common DLBCL, whereas translocation or amplification these very rare. conclusion, independent poor prognostic factor DLBCLs, displays unique clinicopathologic features. Although exact mechanism remains uncertain, consistent activation by alternative pathways other than may contribute pathogenesis.